1. Experience with second-line trabectedin in daily clinical practice: case studies.
- Author
-
Martín-Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Merlini, Alessandra, Ibrahim, Tony, and Le Cesne, Axel
- Abstract
As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female patient with metastatic leiomyosarcoma maintained disease control for 2 years with trabectedin (× 41 cycles) with excellent tolerability and no relevant adverse events. At the time of writing, a male patient with a metastatic solitary fibrous tumor was asymptomatic after 30 cycles of trabectedin and treatment was ongoing. A young male patient with a recurrent, nonresectable, retroperitoneal myxoid/round cell liposarcoma was able to continue his sporting activities (triathlons) over 2 years with trabectedin (× 14 cycles) plus watchful waiting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF